Diagnosis, Staging and Treatment of Patients with Breast Cancer: National Clinical Guideline No. 7

Objectives

This National Clinical Guideline seeks to improve the quality, safety, consistency and cost-effectiveness of breast cancer care in Ireland through nationally applicable, evidence-based recommendations for diagnosis, staging, treatment, monitoring and palliative care.[1]Its wider National Cancer Control Programme mission is to prevent and treat cancer while improving survival and quality of life by translating research and surveillance into action.[2]

• Standardise care for adults with newly diagnosed early or locally advanced breast cancer, particularly where practice varies, evidence is uncertain or emerging, or recommendations may have greatest impact.[3]
• Cover radiology, pathology, surgery, medical oncology, radiation oncology and palliative care through multidisciplinary clinical recommendations.[4]
• Exclude population screening, metastatic breast cancer and breast cancer recurrence from the principal clinical scope.[3]
• Improve clinical decision-making, patient outcomes, quality of life and consistency of care, while promoting effective interventions and discouraging ineffective ones.[5]
• Respond to a rising burden of disease, with female breast cancer incidence projected to increase by 63% by 2040 compared with 2010.[6]

The guideline prioritises risk-adapted, patient-centred treatment choices rather than a uniform treatment pathway.[7]It supports appropriate triple assessment and selective imaging, including breast magnetic resonance imaging where conventional assessment is inconclusive or occult primary cancer is suspected.[8][9]It recommends selective staging investigations, avoiding routine metastatic imaging in asymptomatic pathological stage I and II disease while investigating symptomatic patients regardless of stage and staging asymptomatic stage III and IV disease.[10]

• Offer breast-conserving surgery with radiotherapy or mastectomy, where clinically appropriate, for operable invasive breast cancer and ductal carcinoma in situ.[11][7]
• Promote reconstruction discussions for every patient undergoing mastectomy and support individualised consideration of risk-reducing surgery.[12]
• Use sentinel lymph node biopsy for clinically and radiologically node-negative invasive disease, avoiding unnecessary axillary dissection where evidence supports less invasive management.[13][14]
• Provide risk-adapted adjuvant and neoadjuvant chemotherapy, trastuzumab for eligible human epidermal growth factor receptor 2-positive disease, and endocrine therapy for hormone receptor-positive disease.[15][16][17]
• Integrate early palliative care and continuously assess physical, psychosocial and spiritual needs throughout the cancer illness.[18][19]

Recommendations are intended to combine the best available research evidence with clinical expertise through a transparent, internationally recognised evidence-based methodology.[5]Diagnostic recommendations use Oxford Centre for Evidence-Based Medicine grading, while interventional recommendations use Scottish Intercollegiate Guidelines Network grading; good practice points reflect the clinical experience of the Guideline Development Group.[20][21]

Implementation

Implementation is based on multidisciplinary delivery in acute hospitals and designated cancer centres, with corporate responsibility held by the hospital Chief Executive Officer, General Manager and Clinical Director and professional responsibility held by each multidisciplinary team member for recommendations relevant to their discipline.[22][23]The National Cancer Control Programme provides strategic leadership, while the National Clinical Effectiveness Committee provides national quality assurance, commissioning and alignment with implementation levers.[1]

• Deliver specialist services through eight designated cancer centres and the satellite breast unit at Letterkenny General Hospital, alongside other hospitals providing relevant services such as chemotherapy.[5]
• Appoint a lead clinician for Symptomatic Breast Disease in each cancer centre and use quarterly meetings between the National Cancer Control Programme Cancer Network Manager and cancer-centre leadership for performance monitoring and service planning.[24][25]
• Agree breast cancer care priorities annually through the National Cancer Control Programme and submit them to the Health Service Executive Service Plan.[23]
• Disseminate the guideline through participating professional networks and publication on National Cancer Control Programme and National Clinical Effectiveness Committee websites.[23]
• Document deviations from recommendations and discuss relevant care options with patients, significant others and the multidisciplinary team.[1]

Guideline development and updating use Evidence-Based Practice methods.[3]Clinical questions are structured through the Population, Intervention, Comparator, Outcome and Time framework, developed by discipline-specific groups and approved by the Guideline Development Group.[26]Literature searches prioritise current international guidelines and use primary research where needed, including searches of the Cochrane Library, Medline, Embase, PsycINFO and the Cumulative Index to Nursing and Allied Health Literature.[26]

• Appraise international guidelines with the Appraisal of Guidelines for Research and Evaluation II instrument and primary studies with Scottish Intercollegiate Guidelines Network checklists.[26]
• Formulate recommendations using evidence tables and considered judgement forms that assess evidence quality, consistency, applicability in Ireland, benefits and harms, health-system effects and resource implications.[26][27]
• Engage patients and the public through service-user testing, the Health Service Executive Patient Forum, patient organisations and national stakeholder review.[27]
• Record stakeholder and international expert submissions and amendments, require supporting evidence and conflict-of-interest declarations, and undertake international expert review after revision.[27]
• Update literature searches following internal review and before external review, retain search records, and check cited articles for retraction or withdrawal.[28]

The implementation plan applies the Capability, Opportunity and Motivation behaviour-change model to identify target behaviours, barriers and facilitators during recommendation development.[29]It selects intervention functions such as education, training, enablement, persuasion, restrictions and environmental restructuring, while recognising that no intervention may be needed for existing standard practice.[29]Operational requirements may include access to magnetic resonance imaging, training and equipment for magnetic resonance-guided biopsy, and coordinated imaging and treatment decisions.[30]

Implementation and patient outcomes are to be audited, including key performance indicators agreed through the Breast National Clinical Leads Network and annual multidisciplinary Cancer Quality and Audit Fora.[3][23]Specified audit measures include use of axillary ultrasound in eligible operable invasive cancer, therapeutic breast operations after breast-conserving surgery, clear margins, avoidance of unnecessary early-stage metastatic imaging, hypofractionated radiotherapy, and commencement of radiotherapy alone within 12 weeks of final therapeutic surgery.[31][32]

The National Cancer Registry Ireland is identified as a source for monitoring survival, stage and tumour type, surgical treatment patterns, axillary procedures and residual disease after treatment.[32]The guideline was scheduled for periodic literature surveillance and formal National Cancer Control Programme consideration three years after publication, with interim or three-year updates subject to National Clinical Effectiveness Committee approval.[23]

Monitoring & Evaluation

The guideline establishes a national monitoring and accountability approach combining implementation audit, patient-outcome review, evidence surveillance and structured governance. National Clinical Guidelines and National Clinical Audit are subject to periodic implementation and impact reporting, while the National Clinical Effectiveness Committee publishes an annual report and provides quality assurance.[1]

• Develop and agree Key Performance Indicators through the Breast National Clinical Leads Network, and hold annual multidisciplinary Cancer Quality and Audit Fora.[3]
• Audit implementation and patient outcomes against appendix criteria to assess effects on patient care.[23]
• Monitor cancer-centre performance and service planning through quarterly meetings between the National Cancer Control Programme Cancer Network Manager and each centre’s chief executive officer or general manager.[23]
• Assign corporate responsibility for implementation to hospital chief executive officers, general managers and clinical directors, while multidisciplinary team members remain responsible for recommendations within their disciplines.[22]
• Conduct literature surveillance and submit interim or three-year guideline updates to the National Clinical Effectiveness Committee approval process; the guideline was scheduled for National Cancer Control Programme consideration three years after its June 2015 publication.[23]
• Document stakeholder and international expert-review submissions and resulting amendments in a review log, with feedback supported by evidence and conflict-of-interest declarations.[27]
• Maintain documentation of clinical-question searches, search strategies, results, updates, retracted publications and review of cited evidence.[28]
• Use the Behaviour Change Wheel and COM-B model to assess adoption of specified clinical behaviours, recording implementation barriers and facilitators in considered-judgement forms.[29]
• Measure selected care processes, including the proportion of eligible surgically treated patients receiving axillary ultrasound, the number of therapeutic breast operations after breast-conserving surgery, and commencement of radiotherapy alone within 12 weeks or 84 days of final therapeutic surgery.[31][32]
• Use National Cancer Registry Ireland data to monitor survival by stage and tumour type, surgical treatment patterns, axillary procedure type, and residual tumour status after treatment.[32]
• Monitor cardiac function in patients receiving anthracyclines or trastuzumab, with baseline assessment before treatment.[15]
• Assess palliative-care needs continuously, including at diagnosis, disease progression, changes in functional or social circumstances, patient or family request, and end of life.[19]

Individual clinical sections frequently report evidence outcomes and recommendation grades, but many do not specify routine indicators, targets, reporting frequencies, surveillance systems or independent evaluation arrangements beyond the document-level mechanisms above.[20][21]

Costing & Financing

The guideline was commissioned and funded by the National Cancer Control Programme, while its recommendations were intended to remain independent of funders and grounded in research evidence and clinical expertise.[22]No dedicated implementation budget, allocation, quantified funding gap or resource-mobilisation plan is specified.[33]

• Seek additional resources through the Health Service Executive service-planning process where implementation requires them, and calculate budget impact for recommendations with material resource implications.[23][33]
• Recognise that many recommendations are cost neutral because they reflect current standard practice, although change-related resource implications are considered separately.[23]
• Use economic literature reviews and health-economic appraisal to assess cost-effectiveness, resource impact and applicability of international evidence to Ireland.[33][34]
• Interpret international ratios cautiously because cost-effectiveness thresholds, discount rates, analytical perspectives and healthcare costs differ between settings.[34]
• Apply the conventional Irish range of 20,000 to 45,000 Euros per quality-adjusted life year for non-drug interventions, noting that Ireland has no explicit threshold for these interventions.[34]
• Recognise substantial cancer-related economic burden in Ireland, including 619 million Euros in healthcare costs in 2009, alongside informal-care and productivity losses.[5]
• Consider potential annual savings of up to 940,757.50 Euros from reducing unnecessary staging investigations and imaging.[35]
• Recognise that adjuvant hormone-therapy expenditure fell from 4.9 million Euros in 2013 to 2.2 million Euros in 2015 following drug-price reductions, and support cost-effective tamoxifen prescribing where clinically appropriate.[36]
• Account for service requirements including magnetic resonance imaging access, training and equipment for magnetic resonance-guided biopsy, and potentially increased or reduced imaging demand depending on adoption of recommendations.[30]
• Recognise potential non-monetary resource benefits from less invasive surgery, including fewer repeat procedures, reduced axillary surgery and lymphoedema, and shorter hospital stays.[37]

Economic evidence suggests that some interventions, including sentinel lymph node biopsy and hypofractionated radiotherapy, may offer savings or favourable cost-effectiveness, but estimates depend on modelling assumptions and are not implementation budgets.[35][38]